Feedback
Settings

Settings

Goto Application

6,002 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(USVMJSALORZVDV-SDBHATRESA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 601
1.20250186520ONCOLYTIC VIRUS COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
US - 12.06.2025
Int.Class A61K 35/763
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
763Herpes virus
 Appl.No 18033768 Applicant City of Hope Inventor Jianhua Yu

Provided herein, inter alia, are oncolytic viruses that express recombinant proteins having bispecific activity. The recombinant proteins include a first fusion protein comprising a first Fc domain covalently linked to a chemokine domain, and a second Fc fusion protein comprising a second Fc domain covalently linked to an anticancer therapeutic antibody domain. The recombinant proteins and oncolytic viruses provided herein are contemplated to be effective for the treatment of cancer, particularly by trafficking immune cells to the tumor microenvironment.

2.20250188065LIGHT-CONTROLLED BIOORTHOGONAL TETRAZINE LIGATION
US - 12.06.2025
Int.Class C07D 405/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
 Appl.No 18026330 Applicant The Regents of the University Of California Inventor Neal Devaraj

Disclosed herein, inter alia, is a light-controlled bioorthogonal tetrazine ligation.

3.WO/2025/122817ANTAGONISTIC CD40 ANTIBODIES
WO - 12.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2024/058786 Applicant THE GENERAL HOSPITAL CORPORATION Inventor FAUSTMAN, Denise L.
The disclosure features antagonistic CD40 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the downstream signaling of CD40. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, and inflammatory diseases.
4.20250177403METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
US - 05.06.2025
Int.Class A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
 Appl.No 19043264 Applicant Spruce Biosciences, Inc. Inventor Alexis HOWERTON

Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).

5.20250177404METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS
US - 05.06.2025
Int.Class A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
 Appl.No 19043275 Applicant Spruce Biosciences, Inc. Inventor Alexis HOWERTON

Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).

6.20250179203ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME
US - 05.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No 18818268 Applicant The General Hospital Corporation Inventor Denise L. FAUSTMAN

The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.

7.WO/2025/117965ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME
WO - 05.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2024/058117 Applicant THE GENERAL HOSPITAL CORPORATION Inventor FAUSTMAN, Denise, L.
The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.
8.WO/2025/117906MICROFLUIDIC ASSEMBLY OF RED BLOOD CELL (RBC) LIPIDS AND COMPONENTS FOR ENGINEERING EXTRACELLULAR VESICLES AND NANOPARTICLES
WO - 05.06.2025
Int.Class C12N 5/078
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
 Appl.No PCT/US2024/057980 Applicant OHIO STATE INNOVATION FOUNDATION Inventor REATEGUI, Eduardo
Described herein are microfluidic approaches for the assembly of nanoparticles manufactured from isolated red blood cell (RBC) lipids and components. The engineered nanoparticles (e.g., vesicles) can be used to encapsulate cargo, including active agents such as proteins, nucleic acids (e.g., RNA), and other classes of therapeutic agents. Optionally, the vesicles can be further functionalized with targeting agents.
9.WO/2025/1176977-AZA BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS
WO - 05.06.2025
Int.Class A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
 Appl.No PCT/US2024/057687 Applicant RIBOSCIENCE LLC Inventor HAWLEY, Ronald
The present disclosure provides certain 7-aza bicyclic heteroaryl compounds of Formula (Id) that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases treatable by inhibition of ENPP1. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
10.WO/2025/111589COMPOSITIONS AND METHODS FOR ENHANCING DRUG RESISTANCE IN CELLS
WO - 30.05.2025
Int.Class C12N 15/52
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
52Genes encoding for enzymes or proenzymes
 Appl.No PCT/US2024/057175 Applicant MEDICI THERAPEUTICS, INC. Inventor RESTIFO, Nicholas P.
Disclosed herein are compositions for engineering a human cell comprising a cell modulating agent or a vector encoding the cell modulating agent. Described herein are compositions comprising an engineered cell, wherein the engineered cell is an engineered human cell and comprises a modification such that the engineered cell is more resistant to an alkylating drug or a nucleoside analog relative to a non-engineered human cell. Various methods of treating a disease are provided, including, a method of treating cancer in a subject by administering the cell modulating agents and/or engineered cells as a therapeutic.
# -